Such mutations also result in resistance to targeted therapy BRAK and MEK drugs in melanoma [108,111,115], resistance to cisplatin in oesophageal squamous cell carcinoma [117] and to irradiation therapies in lung cancer [118]. Here, MAP2K7 is linked to melanoma.